A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Name: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Published: 2024
License: Public Domain

Eli Lilly and Company · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

inflammatory-bowel-diseases ulcerative-colitis

ulcerative colitis, ulcerative colitis chronic, cxcr1/2 ligand receptor antagonist, il-23 p19 antibody, gastrointestinal diseases, inflammatory bowel diseases, digestive system diseases, colonic diseases, intestinal diseases, colitis, colitis, ulcerative, anti-inflammatory agents

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 874350
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.